BBLGW - Bone Biologics Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BBLGW

BONE BIOLOGICS CORPORATION

NASDAQ

$4.10

▼ DOWN 4.65% (-0.20)

KEY STATISTICS

Market Cap$784.65 K

52w High$35.95

52w Low$3.50

Dividend Yield—

Frequency—

P/E-1.51

Volume0

Shares Out.1.80M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jeffrey Frelick

COMPENSATION 2026

Salary$300,000

Stock Awards$0

Incentive Plan Pay$100,000

All Other Comp.$0

Total$426,269

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 13, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.—

DEC

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-10	Reverse	1:6
2023-06-07	Reverse	1:30

PRICE

$4.10 ▼ DOWN 4.65% (−$0.20)

OVERLAYS

About Bone Biologics Corporation

https://www.bonebiologics.com ↗

Bone Biologics Corporation develops NELL-1/DBX, a recombinant protein for targeted bone regeneration in spinal fusion and other surgical specialties, licensed from UCLA and based in Burlington, MA.

INDUSTRY

Biotechnology

A PRODUCT BONE BIOLOGICS CORPORATION IS KNOWN FOR

NB1

NB1 is an investigational bone graft substitute combining recombinant NELL-1 with demineralized bone matrix to promote targeted spinal fusion, currently in pilot trials for degenerative disc disease patients.